


STATE OF CONNECTICUT


DEPARTMENT OF PUBLIC HEALTH

Deidre S. Gifford, MD, MPH
Acting Commissioner



Ned Lamont
Governor
Susan Bysiewicz
Lt. Governor

Immunization Program

TO: All CVP Providers
FROM: Mick Bolduc 
Vaccine Coordinator-Connecticut Vaccine Program (CVP)
DATE: May 5, 2021
SUBJECT: Availability of 2 New Vaccines

The primary purpose of this communication is to inform you of the availability of 2 new pediatric vaccines through the CVP beginning July 1, 2021.

DTaP/IPV/HiB/Hep B Vaccine

The Food & Drug Administration (FDA) has approved a new combination vaccine that protects against 6 diseases. Vaxelis™ (CPT Code 90697) is indicated for active immunization for the prevention of diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* type b, and hepatitis b disease. Vaxelis™ is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

The 3-dose schedule for Vaxelis™ consists of a 0.5 mL intramuscular injection at 2, 4, and 6 months of age. The vaccine is stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Children who have received a 3-dose series of Vaxelis™ should complete the primary and pertussis vaccination series with Pentacel®, Quadracel® or Daptacel® according to the respective prescribing information in the approved package inserts. Vaxelis™ may be used to complete the first 3 doses of the 5-dose DTaP series in infants and children who have received 1 or 2 doses of Pentacel® or Daptacel® and are also scheduled to receive the other antigens in Vaxelis™.

A 3-dose series of Vaxelis™ may be administered to infants born to hepatitis B surface antigen (HBsAg)-negative mothers, and who have received a dose of any hepatitis B vaccine prior to or at 1 month of age. Vaxelis™ may be used to complete the hepatitis B vaccination series following 1 or 2 doses of other hepatitis B vaccines, in infants and children born to HBsAg-negative mothers and who are also scheduled to receive the other antigens in Vaxelis™.



Phone: (860) 509-7929 • Fax: (860) 706-5429
Telecommunications Relay Service 7-1-1
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
www.ct.gov/dph

Affirmative Action/Equal Opportunity Employer



Vaxelis™ may be administered to infants and children who have received 1 or 2 doses of inactivated polio vaccine and are also scheduled to receive the other antigens in Vaxelis™. Vaxelis™ may be administered to infants and children who have received 1 or 2 doses of *Haemophilus influenzae* type b conjugate vaccine and are also scheduled to receive the other antigens in Vaxelis™. The full prescribing information for Vaxelis™ is available at:

https://www.merck.com/product/usa/pi_circulars/v/vaxelis/vaxelis_pi.pdf

Beginning July 1, 2021 the CVP will begin supplying Vaxelis™ for routine vaccination of all children 6 months through 59 months of age. If you are planning to order and administer Vaxelis™, please be sure to utilize your existing inventory of vaccines before making the switch to avoid any potential wastage.

New Meningococcal Vaccine

The FDA has also approved a new vaccine for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, & W. MenQuadfi™ (CPT Code 90619) is approved for use in individuals 2 years of age and older. The schedule for MenQuadfi™ is similar to that of Menactra® with a primary dose administered at the 11-12 year adolescent visit and a subsequent booster dose administered to those individuals 15 years of age and older with at least 4 years elapsed since their previous dose of meningococcal conjugate vaccine.

MenQuadfi™ consists of a 0.5 mL intramuscular injection. The vaccine is stored in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). MenQuadfi™ may be administered to children and adolescents who have received a previous dose of Menactra®. More information for MenQuadfi™ is available at:

[Meningococcal Meningitis Vaccine | MenQuadfi™ \(Meningococcal \[Groups A, C, Y, W\] Conjugate Vaccine\).](#)

Beginning July 1, 2021 the CVP will begin supplying MenQuadfi™ for routine vaccination of all adolescents 11 through 18 years of age as well as for any high-risk patients in need of meningococcal conjugate vaccine 2 through 10 years of age. If you are planning to order and administer MenQuadfi™, please be sure to utilize your existing inventory of Menactra® before making the switch to avoid any potential wastage. The CVP will continue to offer Menactra® as long as the vaccine remains available on the federal CDC contract which is expected to be continue through April 2022.

An updated CVP Vaccine Eligibility Criteria as of July 1, 2021 is included below.

As always, if you have any questions, please feel free to contact me at (860) 509-7940.

Connecticut Vaccine Program (CVP) Eligibility Criteria as of July 1, 2021

Vaccine	Age Group	Status of Children VFC and State Supplied Vaccine				CPT Code(s)
		VFC Eligible ¹	Non-VFC Eligible Privately Insured ²	Non-VFC Eligible Under- Insured ²	S-CHIP ²	
Hepatitis B	Newborns in hospital	YES	YES	YES	YES	90744
	Children 0-18 years	YES	YES	YES	YES	
Varicella (Doses 1 & 2)	12 months-18 years ³	YES	YES	YES	YES	90716
Td	7-18 years ⁴	YES	YES	YES	YES	90714
MMR	12 months-18 years	YES	YES	YES	YES	90707
	College (any age)	YES	YES	YES	YES	
MMRV (Doses 1 & 2)	12 months-12 years	YES	YES	YES	YES	90710
DTaP	2 months – 6 years	YES	YES	YES	YES	90700
Hib	2-59 months	YES	YES	YES	YES	90647, 90648
IPV	2 months-18 years	YES	YES	YES	YES	90713
DTaP/IPV	4-6 years	YES	YES	YES	YES	90696
DTaP/IPV/Hep B	2-83 months	YES	YES	YES	YES	90723
DTaP/IPV/Hib	2-59 months	YES	YES	YES	YES	90698
DTaP/IPV/Hib/Hep B	2-59 months	YES	YES	YES	YES	90697
Meningococcal Conjugate High Risk:	2 months-10 years	YES	YES	YES	YES	90619, 90734
	Routine Doses 1 & 2:					
	11-18 years	YES	YES	YES	YES	
Tdap	7-18 years ⁵	YES	YES	YES	YES	90715
Pneumococcal Conjugate (PCV13)	2 months-18 years	YES	YES	YES	YES	90670
Pneumococcal Polysaccharide (PPSV23)	2-18 years	YES	YES	YES	YES	90732
Influenza	6 months-18 years	YES	YES	YES	YES	90672, 90674, 90686
Hepatitis A	12 months -18 years	YES	YES	YES	YES	90633
Rotavirus	6 weeks-8 months	YES	YES	YES	YES	90680, 90681
HPV (males & females)	9-10 & 13-18 years	YES	NO	YES	YES	90651
	11-12 years	YES	YES	YES	YES	
Meningococcal Serogroup B High Risk:	10-18 years	YES	YES	YES	YES	90620, 90621
	Routine Doses 1 & 2:					
	16-18 years	YES	YES	YES	YES	

- VFC eligibility is defined as follows: (a) Medicaid enrolled; (b) NO health insurance; (c) American Indian or Alaskan native; or (d) underinsured seen at an FQHC.
- Non-VFC children refers to patients who have private insurance that covers the cost of immunizations, patients that are under-insured for some or all vaccines seen by a private provider; and S-CHIP children- those children enrolled in HUSKY B.
- Susceptible children who do not have a clinical history of chicken pox.
- Td vaccine can be given to children 7-18 years of age to complete their primary series, or to those children 7-18 years of age who are in need of a Tetanus containing vaccine and cannot receive Tdap.
- Tdap vaccine should be administered routinely to children at the 11-12 year old preventive health care visit, and to children 7-10 & 13-18 years old who have not been fully vaccinated against pertussis and for whom no contraindication to pertussis containing vaccine exists

As of July 1, 2020 the only childhood vaccine not universally available from the CVP is HPV for privately insured patients 9-10 & 13-18 years of age. Providers can purchase this vaccine privately and submit billing requests to the appropriate insurer in accordance with normal billing procedures.